Ucb Biopharma Srl

This study tested a drug called bimekizumab in 505 adults with moderate to severe hidradenitis suppurativa, a chronic skin disease that causes painful boils. The goal was to see if the drug could reduce skin lesions by at least 50% after 16 weeks compared to a placebo. The trial …

This study tested a drug called bimekizumab in 400 adults with active psoriatic arthritis who had not responded well to standard TNF-blocking treatments. The goal was to see if bimekizumab could reduce joint pain and swelling better than a placebo. Results focused on at least 50%…

This study tested a drug called rozanolixizumab in 200 adults with generalized myasthenia gravis, a condition that causes muscle weakness. The goal was to see if the drug improves daily activities like talking, swallowing, and breathing compared to a placebo. Results focused on s…

This study tested an experimental oral drug, UCB0599, in 496 people with early-stage Parkinson's disease. Over 18 months, researchers compared the drug against a placebo to see if it could safely slow down the worsening of movement and daily-life symptoms. The goal was to find a …

This study tested a drug called bimekizumab in 332 adults with active ankylosing spondylitis, a type of arthritis that causes back pain and stiffness. Participants received either the drug or a placebo (fake treatment) for 16 weeks. The main goal was to see if the drug could redu…

This study tested a new drug called bimekizumab against a placebo in 435 adults with moderate to severe plaque psoriasis. The main goal was to see if the drug could clear at least 90% of psoriasis symptoms after 16 weeks. Results showed that bimekizumab was highly effective at re…

This study tested a new medicine called UCB1381 in healthy people and those with moderate to severe eczema (atopic dermatitis). The goal was to see if it is safe and if it can improve skin symptoms like redness and itching. 273 participants took part, and the drug was given as an…

This study tested a drug called bimekizumab in 509 adults with moderate to severe hidradenitis suppurativa, a chronic skin condition that causes painful lumps. The goal was to see if the drug could reduce the number of inflamed bumps and tunnels by at least 50% after 16 weeks com…

This study looked at the long-term safety of bimekizumab in over 1,300 adults with moderate to severe plaque psoriasis. Participants who completed earlier studies received open-label bimekizumab, and researchers tracked side effects over time. The goal was to see how safe and tol…

This study tested a new drug called bimekizumab in 49 adults with moderate to severe plaque psoriasis. The goal was to see how well it worked, how safe it was, and how the body processed the drug. Participants received the drug and were monitored for 28 weeks, with improvements m…

This study looked at 26 adults with generalized myasthenia gravis who switched from an IV infusion to a daily shot of zilucoplan. The main goal was to see if the switch was safe and well-tolerated. Researchers also checked if symptoms stayed under control. The study was completed…

This study tested whether people with generalized myasthenia gravis (gMG) can safely and effectively use an auto-injector to give themselves the drug zilucoplan at home. Thirty-one adults who were already taking zilucoplan participated. The main goal was to see if they could deli…

This study tested a drug called bimekizumab in 274 adults with a form of spinal arthritis that doesn't show up on X-rays (nonradiographic axial spondyloarthritis). The goal was to see if the drug could reduce pain, stiffness, and improve function better than a placebo. The trial …

This study tested a new drug called bimekizumab against an existing treatment (adalimumab) in 478 adults with moderate to severe plaque psoriasis. The goal was to see if bimekizumab could clear skin better at 16 weeks, measured by at least 90% improvement in psoriasis area and se…

This study tested a new drug called bimekizumab in 567 adults with moderate to severe plaque psoriasis. The goal was to see if it could clear skin better than a placebo or another existing treatment. Results focused on how many people achieved at least 90% skin improvement after …

This study tested whether adding brivaracetam to existing epilepsy medications helps reduce partial seizures in adults aged 16 to 80. About 449 participants took either the drug or a placebo for 12 weeks. The main goals were to check safety and see if seizure frequency dropped. R…

This early-stage study tested a new medicine called UCB9741 in 107 people, first in healthy volunteers and then in those with moderate-to-severe atopic dermatitis (eczema). The main goals were to check safety and see if the drug can improve skin symptoms. Researchers measured sid…

This early-stage study tested a new drug called UCB0022 in 100 healthy volunteers and people with Parkinson's disease. The main goal was to check if the drug is safe and how the body processes it. Researchers looked for side effects and measured drug levels in the blood. This is …

This study looked at how a new tablet form of the drug minzasolmin is absorbed by the body compared to an older capsule form. It also checked if eating food changes how the drug works. The study involved 18 healthy adults aged 18 to 55 and is now complete.

This study looked at how much of the drug rozanolixizumab passes into breast milk after a single dose. Fifteen healthy women who were already planning to stop breastfeeding took part. Researchers collected breast milk samples over 7 days to measure drug levels and estimate how mu…

This study tested two different tablet versions of a drug called UCB0022 in 14 healthy adults aged 18 to 55. The goal was to see how much of the drug gets into the blood and if one tablet works better than the other. Researchers also checked for any side effects. This is an early…

This study tested how quickly a new inhaled form of alprazolam (Staccato) affects brain activity compared to two standard sedatives given through a vein or as a nasal spray. Fifty-five healthy adults received single doses of each drug in a random order, and their brain waves were…

This early-stage study tested two new formulations of the experimental drug UCB0599 in 73 healthy adults. Part A looked at how stomach acid levels affect drug absorption, while Part B checked safety and how the drug behaves in people of Japanese and Chinese descent. The goal was …